Recent Analysts’ Ratings Changes for Danaher (DHR)

Danaher (NYSE: DHR) has recently received a number of price target changes and ratings updates:

• 1/29/2026 – Danaher had its “buy” rating reaffirmed by analysts at Deutsche Bank Aktiengesellschaft.
• 1/29/2026 – Danaher was given a new $251.00 price target on by analysts at Robert W. Baird.
• 1/29/2026 – Danaher had its “overweight” rating reaffirmed by analysts at KeyCorp.
• 1/29/2026 – Danaher had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $270.00 to $265.00. They now have a “buy” rating on the stock.
• 1/29/2026 – Danaher had its price target raised by analysts at JPMorgan Chase & Co. from $270.00 to $275.00. They now have an “overweight” rating on the stock.
• 1/28/2026 – Danaher had its price target raised by analysts at Jefferies Financial Group Inc. from $255.00 to $265.00. They now have a “buy” rating on the stock.
• 1/28/2026 – Danaher had its “outperform” rating reaffirmed by analysts at Evercore Inc. They now have a $254.00 price target on the stock.
• 1/20/2026 – Danaher had its price target raised by analysts at The Goldman Sachs Group, Inc. from $265.00 to $270.00. They now have a “buy” rating on the stock.
• 1/16/2026 – Danaher had its price target raised by analysts at Leerink Partners from $260.00 to $270.00. They now have an “outperform” rating on the stock.
• 1/14/2026 – Danaher was given a new $265.00 price target on by analysts at Argus.
• 1/7/2026 – Danaher had its “buy” rating reaffirmed by analysts at TD Cowen.
• 1/7/2026 – Danaher had its price target raised by analysts at TD Cowen from $260.00 to $270.00. They now have a “buy” rating on the stock.
• 1/5/2026 – Danaher had its “outperform” rating reaffirmed by analysts at Evercore Inc. They now have a $250.00 price target on the stock.
• 1/2/2026 – Danaher had its price target raised by analysts at Guggenheim from $250.00 to $275.00. They now have a “buy” rating on the stock.
• 12/29/2025 – Danaher had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 12/22/2025 – Danaher had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 12/18/2025 – Danaher had its “overweight” rating reaffirmed by analysts at KeyCorp.
• 12/17/2025 – Danaher had its price target raised by analysts at Jefferies Financial Group Inc. from $245.00 to $255.00. They now have a “buy” rating on the stock.
• 12/15/2025 – Danaher had its price target raised by analysts at Wells Fargo & Company from $230.00 to $240.00. They now have an “equal weight” rating on the stock.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, January 30th. Stockholders of record on Friday, December 26th were paid a $0.32 dividend. The ex-dividend date of this dividend was Friday, December 26th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.6%. Danaher’s dividend payout ratio is 25.40%.

Insider Activity

In related news, Director Teri List sold 3,298 shares of the stock in a transaction dated Tuesday, November 18th. The stock was sold at an average price of $226.50, for a total transaction of $746,997.00. Following the completion of the transaction, the director directly owned 20,762 shares in the company, valued at approximately $4,702,593. This trade represents a 13.71% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Brian W. Ellis sold 21,776 shares of the business’s stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $219.23, for a total value of $4,773,952.48. Following the completion of the sale, the senior vice president owned 14,553 shares in the company, valued at $3,190,454.19. The trade was a 59.94% decrease in their position. The disclosure for this sale is available in the SEC filing. 11.20% of the stock is currently owned by insiders.

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.